Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Jan 4, 2016 at 10:05 AM EST

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as…

Chris Lange | Jan 2, 2016 at 10:15 AM EST

4 Top FDA Decisions Expected in Q1

24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added…

Chris Lange | Dec 31, 2015 at 10:15 AM EST

Sancilio Pharmaceuticals Files for IPO

Sancilio Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Dec 30, 2015 at 1:05 PM EST

Fitch Ratings Weighs In on the ACA

Fitch commented on the omnibus spending bill signed into law on December 18 that provides U.S. health insurers with a…

Chris Lange | Dec 30, 2015 at 12:25 PM EST

KaloBios Files for Bankruptcy

KaloBios Pharmaceuticals filed for Chapter 11 bankruptcy on Tuesday morning, over a week after former CEO Martin Shkreli was arrested…

Chris Lange | Dec 29, 2015 at 11:55 AM EST

Can NeuroMetrix Turn Itself Around?

NeuroMetrix might be turning itself around with the launch of its system for detecting diabetic neuropathy.

Lee Jackson | Dec 29, 2015 at 10:55 AM EST

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current…

Chris Lange | Dec 28, 2015 at 11:40 AM EST

Valeant CEO Takes Temporary Leave on Health Scare

Valeant Pharmaceuticals watched its shares move lower in Monday’s trading session on a health scare from one of its top…

Chris Lange | Dec 28, 2015 at 10:40 AM EST

Is There Any Hope for Chimerix?

Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.

Chris Lange | Dec 28, 2015 at 10:35 AM EST

AnaptysBio Looking for More Funding in IPO

AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Lee Jackson | Dec 28, 2015 at 10:10 AM EST

Merrill Lynch Has 4 Large Cap Pharmaceutical Dividend Stocks for 2016

These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life.…

Lee Jackson | Dec 28, 2015 at 9:50 AM EST

Could These Hot 2015 Biotech IPOs Be 2016 Buyout Targets?

While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts…

Chris Lange | Dec 28, 2015 at 9:35 AM EST

Major Pharma Short Interest Takes Another Giant Leap Forward

The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical…

Chris Lange | Dec 28, 2015 at 8:40 AM EST

Short Interest Remains Mixed in Major Biotechs

The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in…

Trey Thoelcke | Dec 23, 2015 at 10:40 AM EST

4 Ignored Biotech Stocks for 2016

Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures…

1 … 229 230 231 232 233 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

4 Top FDA Decisions Expected in Q1

Sancilio Pharmaceuticals Files for IPO

Fitch Ratings Weighs In on the ACA

KaloBios Files for Bankruptcy

Can NeuroMetrix Turn Itself Around?

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Valeant CEO Takes Temporary Leave on Health Scare

Is There Any Hope for Chimerix?

AnaptysBio Looking for More Funding in IPO

Merrill Lynch Has 4 Large Cap Pharmaceutical Dividend Stocks for 2016

Could These Hot 2015 Biotech IPOs Be 2016 Buyout Targets?

Major Pharma Short Interest Takes Another Giant Leap Forward

Short Interest Remains Mixed in Major Biotechs

4 Ignored Biotech Stocks for 2016

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential

4 Top FDA Decisions Expected in Q1

Sancilio Pharmaceuticals Files for IPO

Fitch Ratings Weighs In on the ACA

KaloBios Files for Bankruptcy

Can NeuroMetrix Turn Itself Around?

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Valeant CEO Takes Temporary Leave on Health Scare

Is There Any Hope for Chimerix?

AnaptysBio Looking for More Funding in IPO

Merrill Lynch Has 4 Large Cap Pharmaceutical Dividend Stocks for 2016

Could These Hot 2015 Biotech IPOs Be 2016 Buyout Targets?

Major Pharma Short Interest Takes Another Giant Leap Forward

Short Interest Remains Mixed in Major Biotechs

4 Ignored Biotech Stocks for 2016

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation